Ocular Therapeutix Releases 2026 First Quarter Revenue Results

Published on May 7, 2026
BEDFORD, Mass.—Ocular Therapeutix Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company in the retina space, reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights. Ocular Therapeutix reported total cash and cash equivalents of $666.7 million as of March 31, 2026. Based on current plans and anticipated cash inflows from Dextenza, the company believes its cash balance will support planned expenses, debt service obligations, and capital expenditures into 2028.
Continue reading on website
Other news

High-intensity Statin Use Associated with Lower Risk of Progression to Wet AMD

May 7, 2026
High-intensity use of statins, which are widely used to lower cholesterol and reduce the risk of heart attacks and strokes, was associated with lower risk of conversion to wet AMD, preservation of visual function and reduced drusen volume increase. Photo: Getty Images. Click image to enlarge. Age-related macular degeneration (AMD) is a leading cause of vision loss in older a

Kits Eyecare Announces Q1 2026 Results, Reports Record Quarter

May 7, 2026
VANCOUVER, Canada—Kits Eyecare Ltd. (TSX: KITS), a leading vertically integrated eyecare provider based in Canada, announced its financial results for the first quarter ended March 31, 2026, during an investors call on May 6, 2026. For Q1 2026, Kits reported that revenue increased 23 percent year-over-year to a record $57 million CAD, with glasses revenue increasing 61 percent year-over-year to a